Crohn’s Disease (M14-115)

Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of your digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people.

The inflammation caused by Crohn’s disease often spreads deep into the layers of affected bowel tissue. Crohn’s disease can be both painful and debilitating, and sometimes may lead to life-threatening complications.

While there’s no known cure for Crohn’s disease, therapies can greatly reduce its signs and symptoms and even bring about long-term remission. With treatment, many people with Crohn’s disease are able to function well.

This study is a randomized, double-blind multicenter study of two adalimumab induction dosing regimens in subjects with moderately to severely active Crohn’s disease and evidence of mucosal ulceration.

https://clinicaltrials.gov/ct2/show/NCT02065570?term=M14-115&rank=2

Register Today!

Let others know about this Trial!

Trial Information

Start DateMay 2015
End DateTBD
Trial Duration12-15 weeks
Number of Visits9-10 visits
Lead CRCGabriel Theriault
StatusOn-Going

For additional information
on this trial contact:

Phone705-566-0005